Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM Olanzapine in Japanese Agitated Schizophrenia
NCT00485810Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of olanzapine in schizophrenia (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Safety and Efficacy of IM Olanzapine. Started Jun 2004; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00485810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00485810.